Company intelligence / Profile preview

EyeGate Pharmaceuticals

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Clinical-stage pharmaceutical company with Phase 3 trials in anterior uveitis (EGP-437), positive pilot data in dry eye disease (OBG), and clinical-stage PP-001 (DHODH inhibitor) with completed dose-ascending safety studies in Europe for both PaniJect (intravitreal injection) and PaniDrop (eye drop formulation).

Therapeutic areas: Ophthalmology
Modalities: Small moleculeDeviceHydrogel-based drug delivery therapy
Industry: Biotech

Partnerships

Bausch Health Companies

Beyond the preview

Go deeper on EyeGate Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeGate Pharmaceuticals.

Explore the full profile